



ABSTRACT OF THE DISCLOSURE

This invention discloses methods, kits, and instructions to treat neovasculture diseases of the eye through the administration of a targeted photosensitizing agent and subsequent exposure to light of specific wavelength sufficient to photoactivate photosensitizing agent. The photosensitizing agent is bound to a composition that mediates site specific delivery to a neovasculture target tissue of a therapeutically effective amount of a photosensitizing agent that is activated by a relatively low fluence rate of light over a prolonged period of time. Diseases treatable under this invention, include: diabetic retinopathy; macular degeneration; and malignant uveal melanomas.